In a filing, Fate Therapeutics Inc revealed its Chief Financial Officer Dulac Edward J III unloaded Company’s shares for reported $19013.0 on Mar 04 ’24. In the deal valued at $7.77 per share,2,447 shares were sold. As a result of this transaction, Dulac Edward J III now holds 101,479 shares worth roughly $0.7 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Dulac Edward J III sold 1,849 shares, generating $9,245 in total proceeds. Upon selling the shares at $5.00, the Chief Financial Officer now owns 103,926 shares.
Before that, Wolchko J Scott sold 14,391 shares. Fate Therapeutics Inc shares valued at $62,889 were divested by the President and CEO at a price of $4.37 per share. As a result of the transaction, Wolchko J Scott now holds 371,248 shares, worth roughly $2.55 million.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Neutral”. Wedbush also remained covering FATE and has decreased its forecast on January 06, 2023 with a “Neutral” recommendation from previously “an Outperform” rating. Truist revised its rating on January 06, 2023. It rated FATE as “a Hold” which previously was an “a Buy”.
Price Performance Review of FATE
On Tuesday, Fate Therapeutics Inc [NASDAQ:FATE] saw its stock fall -0.15% to $6.86. Over the last five days, the stock has lost -2.00%. Fate Therapeutics Inc shares have risen nearly 83.42% since the year began. Nevertheless, the stocks have risen 27.27% over the past one year. While a 52-week high of $8.83 was reached on 03/07/24, a 52-week low of $1.63 was recorded on 01/03/24. SMA at 50 days reached $6.52, while 200 days put it at $4.00. A total of 2.94 million shares were traded, compared to the trading of 2.0 million shares in the previous session.
Levels Of Support And Resistance For FATE Stock
The 24-hour chart illustrates a support level at 6.65, which if violated will result in even more drops to 6.44. On the upside, there is a resistance level at 7.10. A further resistance level may holdings at 7.34. The Relative Strength Index (RSI) on the 14-day chart is 47.80, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.62, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.03%. Stochastics %K at 20.03% indicates the stock is a holding.
How much short interest is there in Fate Therapeutics Inc?
A steep rise in short interest was recorded in Fate Therapeutics Inc stocks on Feb 29, 2024, growing by 2.01 million shares to a total of 13.49 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 11.48 million shares. There was a rise of 14.9%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 17.40% of the overall stock float, the days-to-cover ratio (short ratio) rose to 4.11.
